The standard regimen involves 1 mg (1000 g) administered intramuscularly on alternate days until there is no further improvement in symptoms, followed by maintenance injections of 1 mg every two months
This flexibility allows for personalized protocols that match individual tolerance levels and goals
10.1080/02699052.2019.1587000 Summary Keywords stroke, GLP-1, GLP-1R agonists, neuroprotection, diabetes Citation Yang X, Qiang Q, Li N, Feng P, Wei W and Hlscher C (2022) Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research
Many patients who hit a plateau also realize they may need to refine their technique or expectations
Why GLP-1 Peptides Must Be Used Under Medical Supervision GLP-1 receptor agonists like Semaglutide and Tirzepatide are not supplements